Kunisada Toshiyuki, Nakata Eiji, Fujiwara Tomohiro, Hata Toshiaki, Sato Kohei, Katayama Haruyoshi, Kondo Ayana, Ozaki Toshifumi
Department of Medical Materials for Musculoskeletal Reconstruction, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1, Shikata-cho, Okayama 700-8558, Japan.
Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1, Shikata-cho, Okayama 700-8558, Japan.
Biomimetics (Basel). 2024 May 15;9(5):294. doi: 10.3390/biomimetics9050294.
Unidirectional porous hydroxyapatite (UDPHAp) was developed as a remarkable scaffold characterized by a distinct structure with unidirectional pores oriented in the horizontal direction and connected through interposes. We evaluated the radiographic changes, clinical outcomes, and complications following UDPHAp implantation for the treatment of bone tumors. Excellent bone formation within and around the implant was observed in all patients treated with intralesional resection and UDPHAp implantation for benign bone tumors. The absorption of UDPHAp and remodeling of the bone marrow space was observed in 45% of the patients at a mean of 17 months postoperatively and was significantly more common in younger patients. Preoperative cortical thinning was completely regenerated in 84% of patients at a mean of 10 months postoperatively. No complications related to the implanted UDPHAp were observed. In a pediatric patient with bone sarcoma, when the defect after fibular resection was filled with UDPHAp implants, radiography showed complete resorption of the implant and clear formation of cortex and marrow in the resected part of the fibula. The patient could walk well without crutches and participate in sports activities. UDPHAp is a useful bone graft substitute for the treatment of benign bone tumors, and the use of this material has a low complication rate. We also review and discuss the potential of UDPHAp as a bone graft substitute in the clinical setting of orthopedic surgery.
单向多孔羟基磷灰石（UDPHAp）被开发为一种卓越的支架材料，其特点是具有独特的结构，水平方向有单向孔隙，并通过插入物相互连接。我们评估了UDPHAp植入治疗骨肿瘤后的影像学变化、临床结果和并发症。所有接受瘤内切除和UDPHAp植入治疗良性骨肿瘤的患者，在植入物内部和周围均观察到良好的骨形成。45%的患者在术后平均17个月时观察到UDPHAp的吸收和骨髓腔的重塑，且在年轻患者中更为常见。84%的患者在术后平均10个月时，术前皮质变薄完全再生。未观察到与植入UDPHAp相关的并发症。在一名患有骨肉瘤的儿科患者中，当腓骨切除后的缺损用UDPHAp植入物填充时，影像学显示植入物完全吸收，腓骨切除部位清晰形成皮质和骨髓。该患者无需拐杖即可行走良好，并参与体育活动。UDPHAp是治疗良性骨肿瘤的一种有用的骨移植替代物，使用这种材料的并发症发生率较低。我们还回顾并讨论了UDPHAp在骨科手术临床环境中作为骨移植替代物的潜力。
